BRAF and neoplasm: Atypical, non-V600 BRAF (aBRAF) mutations have been recognized in recent years as a unique molecular subset, partly due to the increased use of expanded molecular profiling and circulating tumor DNA (ctDNA) analysis in the management of mCRC.